Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Gorringe KL, McCaffrey L, AlKawaz A, Abidi A, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2019 May;32(5):639-649. doi: 10.1038/s41379-018-0180-x. Epub 2018 Nov 14.

PMID:
30429518
2.

Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Gorringe KL, Aleskandarany MA, Alkawaz A, Mittal K, Aneja R, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2019 Jun 7. doi: 10.1038/s41379-019-0286-9. [Epub ahead of print]

PMID:
31175327
3.

The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Haj-Ahmad R, Gorringe KL, AlKawaz A, Mittal K, Ellis IO, Green AR, Rakha EA.

Histopathology. 2019 Jun;74(7):1025-1035. doi: 10.1111/his.13835. Epub 2019 Apr 14.

PMID:
30725481
4.

Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).

Toss MS, Miligy IM, Gorringe KL, AlKawaz A, Khout H, Ellis IO, Green AR, Rakha EA.

Br J Cancer. 2018 Dec;119(12):1518-1526. doi: 10.1038/s41416-018-0337-x. Epub 2018 Nov 9.

PMID:
30410060
5.

Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study.

Toss MS, Miligy IM, Gorringe KL, AlKawaz A, Mittal K, Aneja R, Ellis IO, Green AR, Roxanis I, Rakha EA.

Mod Pathol. 2019 Jun 7. doi: 10.1038/s41379-019-0296-7. [Epub ahead of print]

PMID:
31175326
6.
7.

Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ.

Miligy I, Mohan P, Gaber A, Aleskandarany MA, Nolan CC, Diez-Rodriguez M, Mukherjee A, Chapman C, Ellis IO, Green AR, Rakha EA.

Histopathology. 2017 Aug;71(2):258-268. doi: 10.1111/his.13217. Epub 2017 May 26.

PMID:
28326600
8.

The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.

Borgquist S, Zhou W, Jirström K, Amini RM, Sollie T, Sørlie T, Blomqvist C, Butt S, Wärnberg F.

BMC Cancer. 2015 Jun 11;15:468. doi: 10.1186/s12885-015-1479-3.

9.

Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer.

Cedolini C, Bertozzi S, Londero AP, Seriau L, Andretta M, Agakiza D, Fongione S, Uzzau A, Risaliti A.

Int J Clin Exp Pathol. 2015 Oct 1;8(10):13304-13. eCollection 2015.

10.

The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution.

Miligy IM, Toss MS, Gorringe KL, Lee AHS, Ellis IO, Green AR, Rakha EA.

Br J Cancer. 2019 May;120(11):1075-1082. doi: 10.1038/s41416-019-0436-3. Epub 2019 May 8.

PMID:
31065110
11.
12.

S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.

Emberley ED, Alowami S, Snell L, Murphy LC, Watson PH.

Breast Cancer Res. 2004;6(4):R308-15. Epub 2004 Apr 26.

13.

Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.

Lambein K, Van Bockstal M, Vandemaele L, Van den Broecke R, Cocquyt V, Geenen S, Denys H, Libbrecht L.

Virchows Arch. 2017 Nov;471(5):575-587. doi: 10.1007/s00428-017-2161-8. Epub 2017 May 31.

PMID:
28567637
14.

Biological Markers Predictive of Invasive Recurrence in DCIS.

Nofech-Mozes S, Spayne J, Rakovitch E, Kahn HJ, Seth A, Pignol JP, Lickley L, Paszat L, Hanna W.

Clin Med Oncol. 2008;2:7-18. Epub 2008 Jan 22.

15.

Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.

Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL.

Hum Pathol. 1992 Sep;23(9):974-9.

PMID:
1355464
16.
17.

Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.

Papantoniou V, Sotiropoulou E, Valsamaki P, Tsaroucha A, Sotiropoulou M, Ptohis N, Stipsanelli A, Dimitrakakis K, Marinopoulos S, Tsiouris S, Antsaklis A.

Breast Cancer. 2011 Oct;18(4):286-91. doi: 10.1007/s12282-009-0192-y. Epub 2010 Feb 9.

PMID:
20143189
18.

Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.

Castro NP, Osório CA, Torres C, Bastos EP, Mourão-Neto M, Soares FA, Brentani HP, Carraro DM.

Breast Cancer Res. 2008;10(5):R87. doi: 10.1186/bcr2157. Epub 2008 Oct 17.

19.
20.

Extent of ductal carcinoma in situ within and surrounding invasive primary breast carcinoma.

Crombie N, Rampaul RS, Pinder SE, Elston CW, Robertson JF, Ellis IO.

Br J Surg. 2001 Oct;88(10):1324-9.

PMID:
11578285

Supplemental Content

Support Center